| Nuclear export of proteins and drug resistance in cancer JG Turner, J Dawson, DM Sullivan Biochemical pharmacology 83 (8), 1021-1032, 2012 | 394 | 2012 |
| Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents JG Turner, J Dawson, CL Cubitt, R Baz, DM Sullivan Seminars in cancer biology 27, 62-73, 2014 | 108 | 2014 |
| Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial AI Daud, J Dawson, RC DeConti, E Bicaku, D Marchion, S Bastien, ... Clinical Cancer Research 15 (7), 2479-2487, 2009 | 106 | 2009 |
| XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple … JG Turner, T Kashyap, JL Dawson, J Gomez, AA Bauer, S Grant, Y Dai, ... Oncotarget 7 (48), 78896, 2016 | 94 | 2016 |
| Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition JG Turner, DC Marchion, JL Dawson, MF Emmons, LA Hazlehurst, ... Cancer research 69 (17), 6899-6905, 2009 | 92 | 2009 |
| Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors JG Turner, JL Dawson, S Grant, KH Shain, WS Dalton, Y Dai, M Meads, ... Journal of hematology & oncology 9, 1-11, 2016 | 87 | 2016 |
| CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo JG Turner, J Dawson, MF Emmons, CL Cubitt, M Kauffman, S Shacham, ... Journal of Cancer 4 (8), 614, 2013 | 76 | 2013 |
| Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms B Holkova, EB Perkins, V Ramakrishnan, MB Tombes, E Shrader, ... Clinical cancer research 17 (10), 3388-3397, 2011 | 64 | 2011 |
| Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia K Sweet, R Komrokji, E Padron, CL Cubitt, JG Turner, J Zhou, AF List, ... Clinical Cancer Research 26 (1), 54-60, 2020 | 30 | 2020 |
| Phase I trial of bortezomib (PS-341; NSC 681239) and “nonhybrid”(bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory … B Holkova, M Kmieciak, EB Perkins, P Bose, RC Baz, GD Roodman, ... Clinical cancer research 20 (22), 5652-5662, 2014 | 27 | 2014 |
| Rapid screening of novel agents for combination therapy in sarcomas CL Cubitt, J Menth, J Dawson, GV Martinez, P Foroutan, DL Morse, ... Sarcoma 2013 (1), 365723, 2013 | 19 | 2013 |
| Melphalan and exportin 1 inhibitors exert synergistic antitumor effects in preclinical models of human multiple myeloma JG Turner, Y Cui, AA Bauer, JL Dawson, JA Gomez, J Kim, CL Cubitt, ... Cancer research 80 (23), 5344-5354, 2020 | 15 | 2020 |
| Phase I/II study of liposomal doxorubicin (DOX) in combination with selinexor (SEL) and dexamethasone (DEX) for relapsed and refractory multiple myeloma (RRMM) R Baz, JA Zonder, KH Shain, M Alsina, JB Brayer, M Melody, JG Turner, ... Blood 130, 3095, 2017 | 13 | 2017 |
| Next generation XPO1 inhibitor KPT-8602 for the treatment of drug-resistant multiple myeloma JG Turner, JL Dawson, CL Cubitt, E Baluglo, S Grant, Y Dai, KH Shain, ... Blood 126 (23), 1818, 2015 | 6 | 2015 |
| The synergistic effect of melphalan and XPO1 inhibition in pre-clinical models of multiple myeloma Y Cui, JG Turner, JL Dawson, JA Gomez, KH Shain, MB Meads, E Baloglu, ... Blood 128 (22), 5662, 2016 | 5 | 2016 |
| Phase I study of topotecan, ifosfamide, and etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates JB Perkins, SC Goldstein, JL Dawson, J Kim, TL Field, JS Partyka, ... Clinical Cancer Research 17 (24), 7743-7753, 2011 | 4 | 2011 |
| Combination therapy of selinexor with bortezomib or carfilzomib overcomes drug resistance to proteasome inhibitors (PI) in human multiple myeloma DM Sullivan, T Kashyap, JL Dawson, Y Landesman, S Grant, KH Shain, ... Blood 126 (23), 3048, 2015 | 3 | 2015 |
| KOS-2464, a novel CRM1 inhibitor and a potential drug for multiple myeloma and leukemia JG Turner, JL Dawson, DM Sullivan Cancer Research 72 (8_Supplement), 1771-1771, 2012 | 3 | 2012 |
| The synergistic effect of melphalan and XPO1 inhibition in preclinical models of multiple myeloma JG Turner, Y Cui, J Dawson, C Cubitt, J Gomez, A Bauer, K Shain, ... Cancer research 77, 4049-4049, 2017 | 2 | 2017 |
| Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma Using the XPO1: Inhibitor Selinexor DM Sullivan, JL Dawson, JG Turner Clinical Lymphoma, Myeloma and Leukemia 15, e290, 2015 | 2 | 2015 |
